Slate Pharmaceuticals, a Durham, N.C.-based developer of hormone replacement therapies, has raised $5 million in Series A funding led by T+T Holdings. News of the round was first reported by the Raleigh News & Observer. www.slatepharma.com
Slate Pharmaceuticals, a Durham, N.C.-based developer of hormone replacement therapies, has raised $5 million in Series A funding led by T+T Holdings. News of the round was first reported by the Raleigh News & Observer. www.slatepharma.com
Copyright PEI Media
Not for publication, email or dissemination